Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HTMC0435 tablets in advanced malignant solid tumors
CTR20200573Phase 2Active
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HTMC0435 in Nonhematologic neoplasms, ovarian cancer, breast cancer, prostate cancer (PCa), pancreatic cancer (PC), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Started May 2020; status: active.
02
Drugs
HTMC0435
03
Conditions
Nonhematologic neoplasmsovarian cancerbreast cancerprostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20200573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200573.